In today's market, patent losses and faltering pipelines are causing pharmaceutical companies to reposition currently marketed drugs through reformulation using novel drug delivery technologies. In addition to reformulating products for lifecycle management, pharmaceutical companies are combining drug delivery technologies with their NCEs early in development. 4P Therapeutics is taking advantage of these market trends by providing its partners with novel drug delivery technologies and expertise in product development with fully integrated capabilities. Founded in 2012, 4P Therapeutics is a privately held company based in Atlanta, GA, focused on the development of innovative transdermal products. The company’s team of scientists has vast experience in developing drug delivery products ranging from conventional transdermal systems to novel transdermal systems, utilizing technologies such as skin poration and microneedles. The company’s team also has experience with developing oral drug delivery technologies, medical devices, diagnostics, and vaccines. Drug Development & Delivery recently spoke with Steven Damon, Founder of 4P Therapeutics, to discuss his vision for the company and how 4P intends to create new and innovative transdermal products that meet the needs of patients, physicians, and payers.